Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice

Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice

Objective: Direct-acting antivirals (DAAs) inhibit hepatitis C virus (HCV) infection by targeting viral proteins that play essential roles in the replication process. However, selection of resistance-associated variants (RAVs) during DAA therapy has been a cause of therapeutic failure. In this study...

Full description

Bibliographic Details
Main Authors: Vercauteren, Koen, Brown, Richard J.P., Mesalam, Ahmed Atef, Doerrbecker, Juliane, Bhuju, Sabin, Geffers, Robert, Van Den Eede, Naomi, McClure, C. Patrick, Troise, Fulvia, Verhoye, Lieven, Baumert, Thomas, Farhoudi, Ali, Cortese, Riccardo, Ball, Jonathan K., Leroux-Roels, Geert, Pietschmann, Thomas, Nicosia, Alfredo, Meuleman, Philip
Format: Article
Published: BMJ Publishing Group 2016
Online Access:https://eprints.nottingham.ac.uk/40671/

Similar Items

Similar Items